Eleanor Barton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eleanor Barton has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Alessia Verduri
Respiratory Unit, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, Hospital Policlinico, Modena, Italy
3 shared publicationsBen Carter
Department of Biostatistics and Health Informatics, Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
3 shared publicationsJonathan Hewitt
Division of Population Medicine, School of Medicine, Cardiff University Cardiff, UK
3 shared publications- Nicholas A. Maskell
North Bristol Lung Centre, Southmead Hospital Respiratory Medicine, Bristol, England, UK
3 shared publications Nick A. Maskell
University of Bristol Academic Respiratory Unit, Southmead Hospital, Bristol, UK
3 shared publicationsNick Maskell
University of Bristol Medical School, Bristol, UK
3 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- p. 2600344
Needle aspiration versus intercostal chest drain for secondary spontaneous pneumothorax (the PRINCE-SSP trial): a pragmatic, open-label, multi-centre, non-inferiority, randomised controlled trial
- 3 September 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- p. 2600344
Open AccessNeedle aspiration versus intercostal chest drain for secondary spontaneous pneumothorax (the PRINCE-SSP trial): a pragmatic, open-label, multi-centre, non-inferiority, randomised controlled trial
- Open Access
- 26 August 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Associations of secondary spontaneous pneumothorax characteristics with key clinical outcomes – a prospective cohort study
Background: Evidence guiding management and prognostication of secondary spontaneous pneumothorax (SSP) is scarce. We describe characteristics and outcomes of SSP patients in a prospective UK cohort. Methods: Multi-centre, prospective, observational cohort study of patients presenting with SSP to 21 UK hospitals over 6 months. Predictors of time to discharge, time to spontaneous resolution and 6-month mortality were analysed using competing risks survival analysis, Cox and logistic regression. Results: Of 213 recruited patients, 138 (65%) were male; median age was 68 years. 155 (73%) underwent immediate pleural intervention; 58 (27%) received initial conservative management, of whom 4 subsequently underwent intervention. Median time to discharge was 8 days (IQR 4–21 days). Median time to spontaneous resolution was 3 days (IQR 1–9 days). All-cause 6-month mortality was 22% (n=46). Longer time to discharge was associated with increasing frailty (Subhazard ratio (sHR) 0.29, 95% CI 0.20–0.42), recent exacerbation (sHR 0.66, 95% CI 0.47–0.92) and intervention (0.34, 95% CI 0.22–0.55). Large intercostal chest drains (HR 0.57 95% CI 0.32–0.99), and recent exacerbation (HR 0.61, 95% CI 0.8–0.97) were associated with longer time to spontaneous resolution. Increasing frailty was associated with increased 6-month mortality (OR 10.89, 95% CI 4.03–29.42). Discussion: This represents the largest prospective SSP cohort study to date. These data describe the SSP population and predictors of time to discharge, persistent air leak and mortality. Frailty was associated with poorer outcomes. Recent exacerbation and larger bore chest drain were associated with increased risk of PAL. Conservative management was commonly used, successfully in most cases.
- 26 August 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Open AccessAssociations of secondary spontaneous pneumothorax characteristics with key clinical outcomes – a prospective cohort study
Background: Evidence guiding management and prognostication of secondary spontaneous pneumothorax (SSP) is scarce. We describe characteristics and outcomes of SSP patients in a prospective UK cohort. Methods: Multi-centre, prospective, observational cohort study of patients presenting with SSP to 21 UK hospitals over 6 months. Predictors of time to discharge, time to spontaneous resolution and 6-month mortality were analysed using competing risks survival analysis, Cox and logistic regression. Results: Of 213 recruited patients, 138 (65%) were male; median age was 68 years. 155 (73%) underwent immediate pleural intervention; 58 (27%) received initial conservative management, of whom 4 subsequently underwent intervention. Median time to discharge was 8 days (IQR 4–21 days). Median time to spontaneous resolution was 3 days (IQR 1–9 days). All-cause 6-month mortality was 22% (n=46). Longer time to discharge was associated with increasing frailty (Subhazard ratio (sHR) 0.29, 95% CI 0.20–0.42), recent exacerbation (sHR 0.66, 95% CI 0.47–0.92) and intervention (0.34, 95% CI 0.22–0.55). Large intercostal chest drains (HR 0.57 95% CI 0.32–0.99), and recent exacerbation (HR 0.61, 95% CI 0.8–0.97) were associated with longer time to spontaneous resolution. Increasing frailty was associated with increased 6-month mortality (OR 10.89, 95% CI 4.03–29.42). Discussion: This represents the largest prospective SSP cohort study to date. These data describe the SSP population and predictors of time to discharge, persistent air leak and mortality. Frailty was associated with poorer outcomes. Recent exacerbation and larger bore chest drain were associated with increased risk of PAL. Conservative management was commonly used, successfully in most cases.
- Open Access
- 8 May 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
A prospective national cohort study of patients with secondary spontaneous pneumothorax assessing the impact of frailty at diagnosis on mortality and admission to hospital
Aim: Secondary spontaneous pneumothorax (SSP) most commonly occurs in older patients with known underlying lung disease. Many are frail, but the effect of frailty on outcomes has not been explored previously. This study aims to evaluate the association between frailty and healthcare outcomes in patients with SSP. Methods: Patients with SSP were identified from the national Secure Anonymised Information Linkage databank. Frailty status was assessed using the electronic frailty index. The primary outcome was time from diagnosis to all-cause mortality. Secondary outcomes included time from diagnosis to disease-specific mortality and admission to hospital. Data were analysed using a multilevel Cox proportional hazards regression model, adjusted for age, sex, Welsh Index of Multiple Deprivation, smoking status and comorbidities. Results: Our search identified 3535 individuals diagnosed with SSP between 1 January 2005 and 1 March 2023. By the end of the study, 2102 (59.6%) participants had died with a median follow-up of 683 days (interquartile range 159–1650 days). There was an increasing risk of mortality for those with mild (adjusted hazard ratio (aHR) 1.24, 95% CI 1.10–1.39), moderate (aHR 1.46, 95% CI 1.25–1.70) and severe (aHR 1.83, 95% CI 1.43–2.32) frailty compared to fit individuals. There was also an association between frailty and time to first all-cause hospitalisation, but not disease-specific hospitalisation. Conclusions: Frailty status at diagnosis was an independent predictor of all-cause mortality in patients with SSP. This demonstrates the importance of assessing frailty status to enable clinicians to provide optimised care and make informed decisions about management of patients with SSP.
- 8 May 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Open AccessA prospective national cohort study of patients with secondary spontaneous pneumothorax assessing the impact of frailty at diagnosis on mortality and admission to hospital
Aim: Secondary spontaneous pneumothorax (SSP) most commonly occurs in older patients with known underlying lung disease. Many are frail, but the effect of frailty on outcomes has not been explored previously. This study aims to evaluate the association between frailty and healthcare outcomes in patients with SSP. Methods: Patients with SSP were identified from the national Secure Anonymised Information Linkage databank. Frailty status was assessed using the electronic frailty index. The primary outcome was time from diagnosis to all-cause mortality. Secondary outcomes included time from diagnosis to disease-specific mortality and admission to hospital. Data were analysed using a multilevel Cox proportional hazards regression model, adjusted for age, sex, Welsh Index of Multiple Deprivation, smoking status and comorbidities. Results: Our search identified 3535 individuals diagnosed with SSP between 1 January 2005 and 1 March 2023. By the end of the study, 2102 (59.6%) participants had died with a median follow-up of 683 days (interquartile range 159–1650 days). There was an increasing risk of mortality for those with mild (adjusted hazard ratio (aHR) 1.24, 95% CI 1.10–1.39), moderate (aHR 1.46, 95% CI 1.25–1.70) and severe (aHR 1.83, 95% CI 1.43–2.32) frailty compared to fit individuals. There was also an association between frailty and time to first all-cause hospitalisation, but not disease-specific hospitalisation. Conclusions: Frailty status at diagnosis was an independent predictor of all-cause mortality in patients with SSP. This demonstrates the importance of assessing frailty status to enable clinicians to provide optimised care and make informed decisions about management of patients with SSP.
- Open Access
- 28 June 2024
- Published by Springer Nature
Assessing experience, safety, and outcomes of the Passio Pump Drainage System
- 28 June 2024
- Published by Springer Nature
Open AccessAssessing experience, safety, and outcomes of the Passio Pump Drainage System
- Open Access
- 6 May 2024
- Published by Springer Nature in Research Square
The impact of frailty at diagnosis on mortality and hospital admissions in secondary spontaneous pneumothorax using the SAIL Databank: a study protocol.
Background The prevalence of frailty is increasing as the global population ages. The relationship between frailty and poor outcomes and the utility of frailty indices to assess frailty is well documented. Although secondary spontaneous pneumothorax (SSP) is common, there are no data evaluating the relationship between frailty and outcomes in this condition. This protocol describes an observational study assessing the correlation between frailty and mortality, amongst other clinical outcomes, in patients with SSP.Methods We will use ICD-10 and NHS read codes to identify participants with a first episode of SSP after 1st January 2005 from the SAIL Databank. The participants will be stratified by frailty status using the electronic frailty index (eFI) measured at or near to the time of diagnosis. Baseline data, including patient demographics, comorbidities, smoking status and date of death, will be collected. The eFI will be correlated with clinical outcomes including mortality, time to hospitalisation, length of stay and readmissions. Our primary analysis will be all-cause mortality by eFI, adjusted for age, sex, deprivation, smoking status and comorbidities. The secondary analyses will be disease-specific mortality, time to first hospital admission, length of stay, and readmissions. All analyses will be presented as crude and adjusted HR and OR with associated 95% CIs and p values.Discussion This study will be the first to explore the association between frailty and clinical outcomes in SSP. The eFI has the potential to be used to predict outcomes and guide clinical decision making for complex, multimorbid patients with SSP.
- 6 May 2024
- Published by Springer Nature in Research Square
Open AccessThe impact of frailty at diagnosis on mortality and hospital admissions in secondary spontaneous pneumothorax using the SAIL Databank: a study protocol.
Background The prevalence of frailty is increasing as the global population ages. The relationship between frailty and poor outcomes and the utility of frailty indices to assess frailty is well documented. Although secondary spontaneous pneumothorax (SSP) is common, there are no data evaluating the relationship between frailty and outcomes in this condition. This protocol describes an observational study assessing the correlation between frailty and mortality, amongst other clinical outcomes, in patients with SSP.Methods We will use ICD-10 and NHS read codes to identify participants with a first episode of SSP after 1st January 2005 from the SAIL Databank. The participants will be stratified by frailty status using the electronic frailty index (eFI) measured at or near to the time of diagnosis. Baseline data, including patient demographics, comorbidities, smoking status and date of death, will be collected. The eFI will be correlated with clinical outcomes including mortality, time to hospitalisation, length of stay and readmissions. Our primary analysis will be all-cause mortality by eFI, adjusted for age, sex, deprivation, smoking status and comorbidities. The secondary analyses will be disease-specific mortality, time to first hospital admission, length of stay, and readmissions. All analyses will be presented as crude and adjusted HR and OR with associated 95% CIs and p values.Discussion This study will be the first to explore the association between frailty and clinical outcomes in SSP. The eFI has the potential to be used to predict outcomes and guide clinical decision making for complex, multimorbid patients with SSP.
- Open Access
- 17 April 2024
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 24 (1) , 1-8
The association between frailty and survival in patients with pleural disease: a retrospective cohort study
There are currently no data on the relationship between frailty and mortality in pleural disease. Understanding the relationship between frailty and outcomes is increasingly important for clinicians to guide decisions regarding investigation and management. This study aims to explore the relationship between all-cause mortality and frailty status in patients with pleural disease. In this retrospective analysis of a prospectively collected observational cohort study, outpatients presenting to the pleural service at a tertiary centre in Bristol, UK with a radiologically confirmed, undiagnosed pleural effusion underwent comprehensive assessment and were assigned a final diagnosis at 12 months. The modified frailty index (mFI) was calculated and participants classified as frail (mFI ≥ 0.4) or not frail (mFI ≤ 0.2). 676 participants were included from 3rd March 2008 to 29th December 2020. The median time to mortality was 490 days (IQR 161–1595). A positive association was found between 12-month mortality and frailty (aHR = 1.72, 95% CI 1.02–2.76, p = 0.025) and age ≥ 80 (aHR = 1.80, 95% CI 1.24–2.62, p = 0.002). Subgroup analyses found a stronger association between 12-month mortality and frailty in benign disease (aHR = 4.36, 95% CI 2.17–8.77, p < 0.0001) than in all pleural disease. Malignancy irrespective of frailty status was associated with an increase in all-cause mortality (aHR = 10.40, 95% CI 6.01–18.01, p < 0.0001). This is the first study evaluating the relationship between frailty and outcomes in pleural disease. Our data demonstrates a strong association between frailty and 12-month mortality in this cohort. A malignant diagnosis is an independent predictor of 12-month mortality, irrespective of frailty status. Frailty was also strongly associated with 12-month mortality in patients with a benign underlying cause for their pleural disease. This has clinical relevance for pleural physicians; evaluating patients’ frailty status and its impact on mortality can guide clinicians in assessing suitability for invasive investigation and management. This study is registered with the Health Research Authority (REC reference 08/H0102/11) and the NIHR Portfolio (Study ID 8960).
- 17 April 2024
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 24 (1) , 1-8
Open AccessThe association between frailty and survival in patients with pleural disease: a retrospective cohort study
There are currently no data on the relationship between frailty and mortality in pleural disease. Understanding the relationship between frailty and outcomes is increasingly important for clinicians to guide decisions regarding investigation and management. This study aims to explore the relationship between all-cause mortality and frailty status in patients with pleural disease. In this retrospective analysis of a prospectively collected observational cohort study, outpatients presenting to the pleural service at a tertiary centre in Bristol, UK with a radiologically confirmed, undiagnosed pleural effusion underwent comprehensive assessment and were assigned a final diagnosis at 12 months. The modified frailty index (mFI) was calculated and participants classified as frail (mFI ≥ 0.4) or not frail (mFI ≤ 0.2). 676 participants were included from 3rd March 2008 to 29th December 2020. The median time to mortality was 490 days (IQR 161–1595). A positive association was found between 12-month mortality and frailty (aHR = 1.72, 95% CI 1.02–2.76, p = 0.025) and age ≥ 80 (aHR = 1.80, 95% CI 1.24–2.62, p = 0.002). Subgroup analyses found a stronger association between 12-month mortality and frailty in benign disease (aHR = 4.36, 95% CI 2.17–8.77, p < 0.0001) than in all pleural disease. Malignancy irrespective of frailty status was associated with an increase in all-cause mortality (aHR = 10.40, 95% CI 6.01–18.01, p < 0.0001). This is the first study evaluating the relationship between frailty and outcomes in pleural disease. Our data demonstrates a strong association between frailty and 12-month mortality in this cohort. A malignant diagnosis is an independent predictor of 12-month mortality, irrespective of frailty status. Frailty was also strongly associated with 12-month mortality in patients with a benign underlying cause for their pleural disease. This has clinical relevance for pleural physicians; evaluating patients’ frailty status and its impact on mortality can guide clinicians in assessing suitability for invasive investigation and management. This study is registered with the Health Research Authority (REC reference 08/H0102/11) and the NIHR Portfolio (Study ID 8960).
- Open Access
- 15 February 2024
- Published by Wiley in Respirology Case Reports
- Vol. 12 (2) , e01303
A chylothorax in a young woman: The difficulties of medical management
Lymphangioleiomyomatosis is a rare pulmonary disease affecting women of childbearing age. Whilst chylothorax is a well‐recognized complication of the condition, management strategies aren't well‐defined, have low success rates and are often only available at tertiary or specialist centres. We describe a case of a young woman referred to pleural clinic with a chylous effusion found to be secondary to lymphangioleiomyomatosis. Initial medical management was unsuccessful and recurrent drainages caused significant complications. Remission was ultimately achieved with a combination of mTOR inhibitors and interventional radiology techniques.
- 15 February 2024
- Published by Wiley in Respirology Case Reports
- Vol. 12 (2) , e01303
Open AccessA chylothorax in a young woman: The difficulties of medical management
Lymphangioleiomyomatosis is a rare pulmonary disease affecting women of childbearing age. Whilst chylothorax is a well‐recognized complication of the condition, management strategies aren't well‐defined, have low success rates and are often only available at tertiary or specialist centres. We describe a case of a young woman referred to pleural clinic with a chylous effusion found to be secondary to lymphangioleiomyomatosis. Initial medical management was unsuccessful and recurrent drainages caused significant complications. Remission was ultimately achieved with a combination of mTOR inhibitors and interventional radiology techniques.
- Open Access
- 1 December 2023
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 19 (4) , 230135
The contemporary management of spontaneous pneumothorax in adults
Spontaneous pneumothorax is a common presentation, and there has been a recent surge of research into the condition. With the recent publication of the new British Thoracic Society guidelines and the upcoming European Respiratory Society guidelines, we provide a concise up-to-date summary of clinical learning points. In particular we focus on the role of conservative or ambulatory management, as well as treatment options for persistent air leak and guidance for when to refer to thoracic surgeons for the prevention of the recurrence of pneumothorax.Educational aims: To give up-to-date guidance on the acute management of spontaneous pneumothorax, including the role of conservative or ambulatory management To discuss the different treatment options for persistent air leak. To guide physicians on when to refer patients to thoracic surgeons for the prevention of the recurrence of pneumothorax.
- 1 December 2023
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 19 (4) , 230135
Open AccessThe contemporary management of spontaneous pneumothorax in adults
Spontaneous pneumothorax is a common presentation, and there has been a recent surge of research into the condition. With the recent publication of the new British Thoracic Society guidelines and the upcoming European Respiratory Society guidelines, we provide a concise up-to-date summary of clinical learning points. In particular we focus on the role of conservative or ambulatory management, as well as treatment options for persistent air leak and guidance for when to refer to thoracic surgeons for the prevention of the recurrence of pneumothorax.Educational aims: To give up-to-date guidance on the acute management of spontaneous pneumothorax, including the role of conservative or ambulatory management To discuss the different treatment options for persistent air leak. To guide physicians on when to refer patients to thoracic surgeons for the prevention of the recurrence of pneumothorax.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA3301
Long term association between frailty and survival in patients with pleural disease
Introduction: With an aging global population, understanding how frailty impacts on outcomes is vital. We explored the association between frailty & survival in pleural disease using the modified frailty index (mFI), a 5-item co-morbidity-based risk stratification tool. Aim and Objectives Assess the prevalence of frailty and its association with mortality in pleural disease. Methods and Analysis 676 outpatients with pleural disease were identified from a prospectively collected single-centre UK database and their data and notes retrospectively analysed. Individual mFIs were calculated and correlation with mortality analysed. In subgroup analyses, malignant disease was analysed separately given the poor prognosis independent of frailty. Results: Ages ranged from 23-97 years (mean 70.7, SD 12.5). Positive associations were found between 1 year mortality and both age ≥80 (p=0.002, aHR 1.8, 95% CI 1.24-2.62) and frailty (mFI≥0.4) (p=0.025, aHR 1.72, 95% CI 1.07-2.76). Subgroup analyses found associations between 1 year mortality and both frailty (p<0.0001, aHR 4.36, 95% CI 2.17-8.77) and malignant disease (p<0.0001, aHR 10.4, 95% CI 6.01-18.02). Conclusion: This is the first study exploring the relationship between frailty & outcomes in pleural disease. Older & frail patients and those with malignancy had higher 1 year mortality risk. Identifying frail patients at risk of poor outcomes may guide management and prognosis in pleural disease.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA3301
Long term association between frailty and survival in patients with pleural disease
Introduction: With an aging global population, understanding how frailty impacts on outcomes is vital. We explored the association between frailty & survival in pleural disease using the modified frailty index (mFI), a 5-item co-morbidity-based risk stratification tool. Aim and Objectives Assess the prevalence of frailty and its association with mortality in pleural disease. Methods and Analysis 676 outpatients with pleural disease were identified from a prospectively collected single-centre UK database and their data and notes retrospectively analysed. Individual mFIs were calculated and correlation with mortality analysed. In subgroup analyses, malignant disease was analysed separately given the poor prognosis independent of frailty. Results: Ages ranged from 23-97 years (mean 70.7, SD 12.5). Positive associations were found between 1 year mortality and both age ≥80 (p=0.002, aHR 1.8, 95% CI 1.24-2.62) and frailty (mFI≥0.4) (p=0.025, aHR 1.72, 95% CI 1.07-2.76). Subgroup analyses found associations between 1 year mortality and both frailty (p<0.0001, aHR 4.36, 95% CI 2.17-8.77) and malignant disease (p<0.0001, aHR 10.4, 95% CI 6.01-18.02). Conclusion: This is the first study exploring the relationship between frailty & outcomes in pleural disease. Older & frail patients and those with malignancy had higher 1 year mortality risk. Identifying frail patients at risk of poor outcomes may guide management and prognosis in pleural disease.
- Open Access
- 13 August 2023
- Published by MDPI AG in Geriatrics
- Vol. 8 (4) , 82
Frailty Prevalence and Association with Clinical Outcomes in Interstitial Lung Disease, Asthma, and Pleural Disease
Background: Frailty is a syndrome characterised by increased vulnerability to negative outcomes. Interstitial lung disease (ILD), asthma, and pleural disease are leading causes of morbidity and mortality. We aimed to investigate the prevalence and impact of frailty in adult patients with these diseases. Methods: We conducted a systematic review and meta-analysis, searching PubMed, Web of Science, The Cochrane Library, and EMBASE for studies reporting on frailty in ILD, asthma, and pleural disease. MeSH terms including interstitial lung disease, Idiopathic Pulmonary Fibrosis, Non-specific Interstitial Pneumonia, Chronic Hypersensitivity Pneumonitis, systemic sclerosis-associated ILD, connective tissue disease-associated ILD, and frailty were used as key words. The primary outcome was prevalence of frailty. Where enough contextually homogeneous studies were included, a pooled random-effects meta-analysis was performed with mortality and hospitalisation as the outcomes. Results: The review found three studies relating to frailty in asthma. No studies relating to pleural disease and frailty were identified. The median prevalence in asthma was 9.5% (IQR, 7.8–11.3). Six relevant studies incorporating 1471 ILD patients (age 68.3 ± SD2.38; 50% male) were identified, which were either cohort or cross-sectional design rated either good or fair. The median prevalence of frailty was 48% (IQR, 25–50). There was a positive association between frail ILD patients and increased risk of long-term mortality (pooled OR, 2.33 95%CI 1.31–4.15, I2 9%). One study reported a hospitalization rate of HR = 1.97(1.32–3.06) within 6 months in frail ILD patients. Conclusions: Frailty is very common and associated with increased mortality in patients with ILD. There are still minimal data regarding the prevalence of frailty and its influence on the risk in this population.
- 13 August 2023
- Published by MDPI AG in Geriatrics
- Vol. 8 (4) , 82
Open AccessFrailty Prevalence and Association with Clinical Outcomes in Interstitial Lung Disease, Asthma, and Pleural Disease
Background: Frailty is a syndrome characterised by increased vulnerability to negative outcomes. Interstitial lung disease (ILD), asthma, and pleural disease are leading causes of morbidity and mortality. We aimed to investigate the prevalence and impact of frailty in adult patients with these diseases. Methods: We conducted a systematic review and meta-analysis, searching PubMed, Web of Science, The Cochrane Library, and EMBASE for studies reporting on frailty in ILD, asthma, and pleural disease. MeSH terms including interstitial lung disease, Idiopathic Pulmonary Fibrosis, Non-specific Interstitial Pneumonia, Chronic Hypersensitivity Pneumonitis, systemic sclerosis-associated ILD, connective tissue disease-associated ILD, and frailty were used as key words. The primary outcome was prevalence of frailty. Where enough contextually homogeneous studies were included, a pooled random-effects meta-analysis was performed with mortality and hospitalisation as the outcomes. Results: The review found three studies relating to frailty in asthma. No studies relating to pleural disease and frailty were identified. The median prevalence in asthma was 9.5% (IQR, 7.8–11.3). Six relevant studies incorporating 1471 ILD patients (age 68.3 ± SD2.38; 50% male) were identified, which were either cohort or cross-sectional design rated either good or fair. The median prevalence of frailty was 48% (IQR, 25–50). There was a positive association between frail ILD patients and increased risk of long-term mortality (pooled OR, 2.33 95%CI 1.31–4.15, I2 9%). One study reported a hospitalization rate of HR = 1.97(1.32–3.06) within 6 months in frail ILD patients. Conclusions: Frailty is very common and associated with increased mortality in patients with ILD. There are still minimal data regarding the prevalence of frailty and its influence on the risk in this population.